Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ReLiV

Financiado

Real time Liver disease early diagnosis through exhaled Volatile Organic Compoun...

Real time Liver disease early diagnosis through exhaled Volatile Organic Compounds sensing The analysis of volatile organic compounds (VOCs) in exhaled breath with nano sensors has great potential to transform healthcare, with accurate, inexpensive, real-time diagnostics. However, attempts to implement this strategy hav... ver más

30/04/2027

NANOSE MEDICAL LTD

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

NANOSE MEDICAL LTD No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-12

HORIZON-EIC-2023-TRANSITIONCHALLENGES-01: EIC Transition Challenge: Full scal... Scope:The scope of the Challenge is the maturation of Micro-Nano-Bio technologies developed in previ...

I+D

Cerrada hace 1 año

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

NANOSE MEDICAL LTD

2.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

VOLATEVS Analysis of the volatile organic compounds emitted by extrac... 1M€ Cerrado

SWEATPATCH Remote SWEATSkin PATCH for Monitoring Breast Cancer Therapeu... 3M€ Cerrado

PID2020-119326RA-I00 ANALYSIS POINT-OF-CARE EN MUESTRAS MINIMAMENTE INVASIVAS EMP... 56K€ Cerrado

PID2021-123183OB-I00 PLATAFORMAS SENSORAS ELECTROQUIMICAS BASADAS EN ACIDOS NUCLE... 169K€ Cerrado

RealCare Real-time biomarker detection systems for rapid medical deci... 9M€ Cerrado

CTQ2013-47993-P METODOLOGIAS RAPIDAS PARA LA DETECCION Y CUANTIFICACION DE B... 111K€ Cerrado

Duración del proyecto: 37 meses Fecha Inicio: 2024-03-12
Fecha Fin: 2027-04-30

Líder del proyecto

NANOSE MEDICAL LTD No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 2M€

Descripción del proyecto The analysis of volatile organic compounds (VOCs) in exhaled breath with nano sensors has great potential to transform healthcare, with accurate, inexpensive, real-time diagnostics. However, attempts to implement this strategy have failed to reach clinical deployment. Firstly, many efforts try to identify the complex mixture of VOCs associated with disease, which is a long and expensive process. Secondly, commercially available sensors require high operating temperatures and have low sensitivity to breath VOCs. NaNose Medical has overcome these limitations through DiaNose, an easy to use, hand-held diagnostics device with potential applicability in >20 different diseases. Instead of identifying individual VOCs, DiaNose deploys an array of patented cross-reactive sensors delivering a chemical signature of breath that can be classified as healthy or diseased through artificial intelligence. Our initial alpha prototype focuses on a key clinical indication: Non-Alcoholic Fatty Liver Disease (NAFLD): with a global prevalence of 30%, it is the leading cause of liver related morbidity, generating an annual burden in Europe of > €35 billion and a further €200 billion of societal costs. Crucially, NAFLD diagnostics present key limitations: liver biopsies are expensive, invasive and subject to sampling error, and non-invasive alternatives lack precision, are operator-dependent, and require expert interpretation. DiaNose will fill this gap, aiming to achieve a diagnostic accuracy of >90% at <50€/test. Lab testing of our alpha prototype has shown high accuracy (88%) with NAFLD models. With the ReLiV project, we will develop an advanced beta prototype that will be validated in clinical settings across different locations. This will bring DiaNose one step closer to commercialization, providing a truly cost-effective, point-of-care detection and monitoring device capable of improving patient outcomes and alleviating the economic burden generated by the growing NAFLD pandemic.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores